Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544).
Our PD(L)anner reports are now hitting the airwaves.
In this edition of Meet the Team, we’re chatting to someone who is bordering on national treasure territory. Lisa Urquhart is the editor of Evaluate Vantage where she…
300 million people worldwide are living with a rare disease. The "orphan" drugs created to treat them have been a fast-growing part of the pharma market for…
It’s Meet the Team time again and to kick off 2023 we’re hopping across the pond to meet one of our US-based team members, Tom Moore, SVP Account Management - Americas.…
Missed out latest webinar? Fear not, here are three things we learned from the 2023 Preview discussion. And the webinar is available on demand now.
Got 10 minutes? Grab a coffee and listen to our latest podcast diving into some of the big oncology catalysts we’ll be looking out for.
Few people are expecting biopharma to stage a spectacular comeback in 2023 but what can we reasonably hope for - and when?
The black box. That mysterious widget in which myriad magic tricks reside. For some it is a magical force that delivers exactly what you need, even if you don’t entirely…
The real start to the biopharma year, the JP Morgan Healthcare Conference, is nearly upon us. As the holidays fade into memory – along with a pretty rough 2022 – what…